Contribute Try STAT+ Today

And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Under the circumstances, however, our agenda is indefinitely going to be exceedingly modest. We hope to observe a day of rest — and a break from the barrage of disturbing events — and catch up on our napping and reading. We may also play a John Prine song or two. And what about you? This may be a good time to figure out how to stock the pantry while avoiding other humans. You could binge watch on the telly or take a needed walk. Or reach out to someone isolated who might like to hear your voice. Well, whatever you do, find a way to cope. And be safe. See you soon.

Since President Trump touted the decades-old malaria drug hydroxycholoroquine as a possible treatment for Covid-19, the number of exposure cases has more than doubled, Forbes writes, citing the American Association of Poison Control Centers. From March 18 through April, poison control centers managed 76 cases, up from 35 cases during the same period a year earlier. An exposure case refers to someone who may have been exposed to a toxic substances. Most of the cases were not toxic.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.